Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-0116PMID 18765555PMCID PMC2656367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2007

  2007cited by this paper
• An Evidence‐based Staging System for Cutaneous Melanoma 1

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

  2003cited by this paper
• Inability to Immunize Patients with Metastatic Melanoma Using Plasmid DNA Encoding the gp100 Melanoma-Melanocyte Antigen

  2003cited by this paper
• Interleukin-2: clinical applications.

  2002cited by this paper
• In vitro studies with bendamustine: enhanced activity in combination with rituximab.

  2002cited by this paper
• Guidelines for the Safe Administration of High-Dose Interleukin-2

  2001cited by this paper
• Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens.

  1999cited by this paper
• Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

  1999influential reference
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper
• Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.

  1998cited by this paper
• Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma.

  1998cited by this paper
• Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

  1998cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects.

  1998cited by this paper
• High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.

  1997cited by this paper
• Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

  1996cited by this paper
• Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

  1996cited by this paper
• Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

  1996cited by this paper
• Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin‐2 Alone

  1995cited by this paper
• Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

  1994cited by this paper
• Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2

  1994cited by this paper
• Cutaneous melanoma.

  1993cited by this paper
• Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• Recent Advances in Molecular Research and Treatment for Melanoma in Asian Populations

  2025cites this paper
• Therapy of 4T1 breast cancer in mice with Vaccinia virus encoding tumor-associated antigen epitopes and mouse IL2 cytokine

  2025cites this paper
• Research hotspots and trends of immunotherapy and melanoma: A bibliometric analysis during 2014–2024

  2025cites this paper
• IL-2 complex therapy prolongs fully MHC-mismatched murine cardiac allograft survival.

  2025cites this paper
• Selectivity of bovine interleukin-2 mutein stimulation on bovine peripheral blood mononuclear cells

  2025cites this paper
• HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion.

  2025cites this paper
• Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines

  2025cites this paper
• Advanced cytokine-based immunotherapies: targeted cis-delivery strategies for enhanced anti-tumor efficacy and reduced toxicity

  2025cites this paper
• In Silico tool for predicting, designing and scanning IL-2 inducing peptides

  2025cites this paper
• Loss of p14 diminishes immunogenicity in melanoma via non‐canonical Wnt signaling by reducing the peptide surface density

  2024cites this paper
• IL-2 based cancer immunotherapies: an evolving paradigm

  2024cites this paper
• Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy

  2024cites this paper
• Into the Future: Fighting Melanoma with Immunity

  2024cites this paper
• Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma.

  2024cites this paper
• RNA-encoded interleukin-2 with extended bioavailability amplifies RNA vaccine-induced antitumor T-cell immunity.

  2024cites this paper
• Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

  2024cites this paper
• IL-2-loaded Polypeptide Nanoparticles for Enhanced Anti-cancer Immunotherapy

  2023cites this paper
• Metastases in the gallbladder from primary anorectal malignant melanoma: A case report.

  2023cites this paper
• The Role of Cytokine IL-2 In Cancer Immunotherapy

  2023cites this paper
• CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours

  2023cites this paper
• CD25: A potential tumor therapeutic target

  2022cites this paper
• Checkpoint inhibitor/interleukin‐based combination therapy of cancer

  2022cites this paper
• Molecular and cellular factors determining the functional pleiotropy of cytokines

  2022cites this paper
• Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

  2022cites this paper
• Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma

  2022cites this paper
• Emerging new therapeutic antibody derivatives for cancer treatment

  2022cites this paper
• Therapeutic potential of interleukin-2 in autoimmune diseases.

  2022cites this paper
• Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007–2018

  2021cites this paper
• Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity

  2021cites this paper
• Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

  2021cites this paper
• Immersion in the search for effective cancer immunotherapies

  2021cites this paper
• Inference of molecular structure for characterization and improvement of clinical grade immunocytokines.

  2021cites this paper
• Multiplexed Immunohistochemistry and Digital Pathology as the Foundation for Next-Generation Pathology in Melanoma: Methodological Comparison and Future Clinical Applications

  2021cites this paper
• Cancer immunotherapy: A comprehensive appraisal of its modes of application.

  2021influential citation
• In silico model for predicting IL-2 inducing peptides in human

  2021cites this paper
• Immunotherapy for HPV Malignancies.

  2021cites this paper
• Metastatic melanomas: Treatment overview

  2021cites this paper
• Cancer vaccines: translational strategies

  2021cites this paper
• Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors

  2021cites this paper
• Chimeric antigen receptor T-cell therapy for melanoma

  2021cites this paper
• MK‐6, a novel not‐α IL‐2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance

  2021cites this paper
• Resolution of Metastatic Subungal Eccrine Porocarcinoma Treated with Intralesional Interleukin-2

  2020cites this paper
• Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8+ T Cell Responses

  2020cites this paper
• Biotherapy for anorectal malignant melanoma : a case report and literature review

  2020cites this paper
• NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer

  2020cites this paper
• Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

  2020cites this paper
• Pulmonary metastasectomy in the era of targeted therapy and immunotherapy

  2020cites this paper
• Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma

  2020cites this paper
• Human leukocyte antigen (HLA) and cancer immunotherapy: HLA-dependent and -independent adoptive immunotherapies

  2020cites this paper
• Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T-Cells in Cancer Immunotherapy

  2020cites this paper
• Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy.

  2020cites this paper
• Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity

  2019cites this paper
• Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma

  2019cites this paper
• Opportunities and challenges for the development of covalent chemical immunomodulators.

  2019cites this paper
• Cutaneous Melanoma , Version 2 . 2019

  2019cites this paper
• A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

  2019cites this paper
• Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial

  2019cites this paper
• Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.

  2019cites this paper
• An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.

  2019cites this paper
• Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice

  2019cites this paper
• Immuno-Oncology in the Era of Personalized Medicine.

  2019cites this paper
• Lithraea caustic (Litre) Extract Promotes an Antitumor Response Against B16 Melanoma

  2019cites this paper
• Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

  2019cites this paper
• ER‐aminopeptidase 1 determines the processing and presentation of an immunotherapy‐relevant melanoma epitope

  2019cites this paper
• Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy

  2018cites this paper
• Immune checkpoint inhibitors: new strategies to checkmate cancer

  2018cites this paper
• Evaluation of the Active Targeting of Melanin Granules after Intravenous Injection of Dendronized Nanoparticles.

  2018cites this paper
• Immunotherapies: Exploiting the Immune System for Cancer Treatment

  2018cites this paper
• NK Cell-Based Immunotherapy in Cancer Metastasis

  2018cites this paper
• Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.

  2018cites this paper
• Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen

  2018influential citation
• Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition

  2018cites this paper
• Mapping Determinants of Cytokine Signaling via Protein Engineering

  2018cites this paper
• Therapeutic targets of FDA-approved immunotherapies in oncology

  2018cites this paper
• Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques

  2018cites this paper
• Cancer Immunotherapy: Whence and Whither

  2017cites this paper
• The emerging role of anti‐CD25 directed therapies as both immune modulators and targeted agents in cancer

  2017cites this paper
• The potential and promise of IL-15 in immuno-oncogenic therapies.

  2017cites this paper
• Interleukin-2 Immunotherapy for Advanced Cancer

  2017cites this paper
• Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.

  2017cites this paper
• Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years’ Experience: A Meta-Analysis of 3312 Patients

  2017cites this paper
• Research progress in advanced melanoma.

  2017cites this paper
• Challenges in Conducting Clinical Research on Patients With Advanced Melanoma.

  2017cites this paper
• Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms’ tumor 1 protein

  2017cites this paper
• The Optimal Impulsive Drug Schedule for Cancer Immunotherapy

  2017cites this paper
• Chapter 20 Therapeutic Agents for Advanced Melanoma

  2017cites this paper
• Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine

  2017cites this paper
• High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions

  2017cites this paper
• Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

  2016cites this paper
• Peptide-Based Cancer Vaccine Strategies and Clinical Results.

  2016cites this paper
• Improving the clinical impact of biomaterials in cancer immunotherapy

  2016cites this paper
• Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

  2016cites this paper
• Cancer Immunotherapy with Interleukin-2—Current Status and Future Developments

  2016cites this paper
• Evaluation of the antitumor efficacy of peptide-coated conditionally replicating adenovirus (PeptiCRAd)

  2016influential citation
• Harnessing the immune system for the treatment of melanoma: current status and future prospects

  2016cites this paper
• Role of IL-2 in cancer immunotherapy

  2016cites this paper
• NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

  2016influential citation
• Regulatory T cells: balancing protection versus pathology.

  2016cites this paper
• Immunotherapy Cancer Immunotherapy with Interleukin-2 — Current Status and Future Developments

  2016cites this paper
• Simulation of Tumor Response to Immunotherapy Using a Hybrid Cellular Automata Model

  2016cites this paper